Dubai, 25th September 2014. Fluxion Biosciences, Inc. (San Francisco, USA) signed an exclusive master distribution agreement with the Alliance Global Group (Dubai, UAE) to bring Fluxion Biosciences innovative microfluidics systems, the ISOFLUX and BIOFLUX systems, into AGBL’s emerging markets.
The IsoFlux™ Cell Separation System allows for variant detection from circulating tumor cells (CTCs) obtained from a routine blood draw using the latest advances in Next-Generation Sequencing (NGS), whereas the BioFlux Systemenables a wide variety of live cell-based assays in the fields of Immunology, Vascular Biology, Microbiology, Cancer Research, Stem Cells, and more. “We believe that Fluxion’s products will offer our customers great tools for researching Circulating Tumor Cells variants, and that it greatly complements our NGS product” says Dr. Dina Amer, Life Sciences Senior Product Manager at Alliance Global Group.
Scientists at Alliance Global Group believe that FluxionBio’s systems are designed to replace laborious and difficult assays by providing intuitive, easy-to-use instruments for cell-based analyses.
About Fluxion Biosciences
Fluxion Biosciences brings the power of cellular analysis to the benchtop with advanced tools to automate complex assays. The company’s IsoFlux System enables translational oncology research using a non-invasive Blood Biopsy™. This platform utilizes high-sensitivity CTC collection to facilitate broad-based genomic analysis using tools such as NGS. This approach provides a more comprehensive look at the disease status, as compared to alternative approaches that only look at limited panels of known mutations. Fluxion’s other products, the BioFlux and IonFlux Systems, have helped hundreds of research institutions and pharmaceutical companies around the world advance their cellular research and drug discovery. The Fluxion products are for Research Use Only and not for use in diagnostic procedures.
For more information, please visit: http://fluxionbio.com/